Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation.
Joseph W KimDana B CardinUlka N VaishampayanShumei KatoSteven R GrossmanPeter M GlazerYu ShyrS Percy IvyPatricia M LoRussoPublished in: The oncologist (2021)
Cediranib and olaparib combination did not result in clinically meaningful activity in patients with mPDAC without gBRCAmt.
Keyphrases